Starpharma (ASX:SPL) has announced the appointment of Justin Cahill as its chief financial officer and company secretary.
Mr Cahill, who will commence in the role in early April 2023, is currently the chief financial officer at Paradigm Biopharmaceuticals.
He previously worked for CSL for almost ten years where he held a number of senior financial and leadership roles, including five years as a divisional chief financial officer at CSL Plasma in the US.
In that role, Mr Cahill provided financial and strategic support to the organisation during a period of significant business expansion where the number of collection centres in the US increased from 65 to 130.
He was CSL's finance integration lead for the $250 million acquisition of the Novartis influenza business in 2015.
"Justin is an accomplished CFO and corporate leader with more than 15 years' experience in finance leadership roles, with the majority being in the healthcare and pharmaceutical sector," said Starpharma CEO Dr Jackie Fairley.
"He has extensive industry knowledge and international experience having worked across large global businesses and smaller growing companies, including a number of ASX-listed companies during periods of rapid growth. Justin is an excellent addition to Starpharma's Executive Team, and we look forward to welcoming him in April."
"I am excited to be joining Starpharma as CFO and Company Secretary, having followed the company for a number of years. I am impressed by Starpharma's deep portfolio of oncology assets, global partnerships, and marketed products as well as the Company's positive culture," added Mr Cahill.
